ライフサイエンスコーパス: graft thrombosis

1 rejection (AMR), complement activation, and graft thrombosis.

2 Graft failures with UW resulted from graft thrombosis.

3 enced a symptomatic or asymptomatic vascular graft thrombosis.

4 he first 90 days largely related to pancreas graft thrombosis.

5 allograft venous outflow drainage that risk graft thrombosis.

6 y would not result in a reduced frequency of graft thrombosis.

7 aspirin and clopidogrel in the prevention of graft thrombosis.

8 ACE inhibition in reducing the risk of acute graft thrombosis.

9 vascular perturbations underlying synthetic graft thrombosis.

10 age was the most significant risk factor for graft thrombosis.

11 ssion of splenic vein thrombosis to complete graft thrombosis.

12 ly significant reduction in the incidence of graft thrombosis.

13 te rejection (17.0% vs. 12.1%), and pancreas graft thrombosis (2.6% vs. 1.3%).

14 arotomy were hemorrhage (59.3%) and vascular graft thrombosis (22.2%).

15 ction and graft pancreatitis (38%), pancreas graft thrombosis (27%), and anastomotic leak (15%).

16 ALI events occurred as a result of surgical graft thrombosis (56%), followed by native vessel in sit

17 sulfate is a novel risk factor for dialysis graft thrombosis after endovascular interventions.

18 ic hypotension with prosthetic arteriovenous graft thrombosis after multivariable adjustment.

19 Reexploration for suspected graft thrombosis after pancreas transplantation resulted

20 Vascular graft thrombosis and bleeding are two major issues that

21 gram because of an unacceptable incidence of graft thrombosis and death.

22 lant IgA-aB2GP1 was the main risk factor for graft thrombosis and early graft loss.

23 type, including PAD resulting from surgical graft thrombosis and in-situ thrombosis.

24 from a combination of primary nonfunction or graft thrombosis and sepsis.

25 targeted gene therapy to prevent acute vein graft thrombosis and the use of folic acid to limit graf

26 ing leaking at the enteric anastomosis site, graft thrombosis, and intraabdominal abscess formation h

27 fect the incidence of polytetrafluorethylene graft thrombosis, and they thus represent a potential tr

28 Graft thrombosis as a cause of graft failure was seen in

29 pathology of the pancreas varied widely with graft thrombosis as the most common finding.

30 arried out, obtaining patients with complete graft thrombosis by Doppler ultrasound.

31 aft function, early rejection treatment, and graft thrombosis did not differ.

32 The incidence of graft thrombosis fell from 48% in 1988 to 17% in 1994 (P

33 Graft thrombosis following pancreas transplantation is t

34 Patients with graft thrombosis had higher free and total indoxyl sulfa

35 articipants who had not experienced previous graft thrombosis (hazard ratio, 0.52; 95% CI, 0.22 to 1.

36 e interval, 4.81-9.37) and, prominently, for graft thrombosis (hazard ratio, 14.75; 95% confidence in

37 The incidence of graft thrombosis in group 1 (31.2%) was significantly hi

38 primary nonfunction; one living-related for graft thrombosis in the face of fungal infection and bil

39 associated with a lower rate of fistula and graft thrombosis, independent of intradialytic hypotensi

40 No major surgical complications such as graft thrombosis, intra-abdominal infection, or abscess

41 Graft thrombosis is the most common cause of early graft

42 Pancreas graft thrombosis is the most common cause of technical g

43 Hemodialysis access (fistula or graft) thrombosis is an unfortunately common and costly

44 Gene therapy strategies for decreasing graft thrombosis may require expression of antithromboti

45 Graft thrombosis occurred in 0% (0/9) of SK recipients i

46 gA-aB2GP1 was an independent risk factor for graft thrombosis (odds ratio, 5.047; P < 0.001).

47 y, is most frequently caused by acute bypass graft thrombosis or in situ thrombosis of a diseased ves

48 Proportion of participants experiencing graft thrombosis or radiological or surgical interventio

49 ary endpoints were the incidence of vascular graft thrombosis, postoperative sepsis, patient, and gra

50 Early postoperative graft thrombosis remain a challenge with pediatric en bl

51 leak (n = 7), aortoduodenal fistula (n = 2), graft thrombosis/stenosis (n = 7), limb separation or fa

52 s a significant decrease in the incidence of graft thrombosis; the authors believe this lower inciden

53 One patient developed stent-graft thrombosis; the prior biliary-TIPS fistula was see

54 We estimated that the odds of graft thrombosis was 1.67 times higher in DCD organs (95

55 Graft thrombosis was found on routine Doppler ultrasound

56 Using multivariate Cox regression analysis, graft thrombosis was independently predicted by absolute

57 Increased incidence of early graft thrombosis was seen in grafts from older donors an

58 was performed monthly for 10 months or until graft thrombosis, with measurement of stenosis at each t

59 Clinical outcomes were partial and complete graft thrombosis within 30 days, bleeding events, relapa

60 subsequent alloantibody formation and led to graft thrombosis without prominent dermal infiltration.